Note 7 - Stockholder's Equity

9 Months Ended

Sep. 30, 2016

Notes to Financial Statements

Stockholders' Equity Note Disclosure [Text Block]

7. Stockholder’s Equity

Common Stock

In connection with the reverse merger, as discussed in Note 4, the Company ascribed non-cash consideration of $384,000 to 478,200 warrants outstanding prior to the reverse merger. During the nine months ended September 30, 2016, the Company is deemed to have issued 2,226,698 shares of its common stock of which 1,861,503 are shares held by the former shareholders of RestorGenex immediately prior to the completion of the Merger, 45,643 shares were issued for advisory services provided to Diffusion LLC in connection with the Merger, 102,430 shares were issued for general financial advisory services provided to Diffusion Pharmaceuticals Inc. and 217,122 shares were issued pursuant to conversions of convertible debt as discussed in Note 6. The Company did not purchase or retire any shares of its common stock.

Legacy RestorGenex Warrants

During the nine months ended September 30, 2016, the Company did not grant any warrants to purchase shares of its common stock and no warrants were exercised. During the nine months ended September 30, 2016, warrants to purchase an aggregate of 17,479 shares of common stock expired unexercised.

Warrants to purchase an aggregate of 460,721 shares of the Company’s common stock were outstanding and exercisable as of September 30, 2016, with per share exercise prices ranging from $20.00 to $750.00 and a weighted average exercise price of $54.27 per share.